A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism.
Article Details
- CitationCopy to clipboard
Eyal Z, Matzov D, Krupkin M, Paukner S, Riedl R, Rozenberg H, Zimmerman E, Bashan A, Yonath A
A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism.
Sci Rep. 2016 Dec 13;6:39004. doi: 10.1038/srep39004.
- PubMed ID
- 27958389 [ View in PubMed]
- Abstract
The increasing appearance of pathogenic bacteria with antibiotic resistance is a global threat. Consequently, clinically available potent antibiotics that are active against multidrug resistant pathogens are becoming exceedingly scarce. Ribosomes are a main target for antibiotics, and hence are an objective for novel drug development. Lefamulin, a semi-synthetic pleuromutilin compound highly active against multi-resistant pathogens, is a promising antibiotic currently in phase III trials for the treatment of community-acquired bacterial pneumonia in adults. The crystal structure of the Staphylococcus aureus large ribosomal subunit in complex with lefamulin reveals its protein synthesis inhibition mechanism and the rationale for its potency. In addition, analysis of the bacterial and eukaryotes ribosome structures around the pleuromutilin binding pocket has elucidated the key for the drug's selectivity.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Lefamulin 50S ribosomal protein L22 Protein Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) YesBinderDetails